Erasca (ERAS) Enterprise Value (2020 - 2026)
Erasca posted quarterly Enterprise Value of -$243.8 million for Q1 2026, up 19.96% year-on-year from -$203.2 million in Q1 2025, and up 11.7% on a QoQ basis from -$276.1 million in Q4 2025.
Erasca (ERAS) has 7 years of Enterprise Value data on file, last reported at -$243.8 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 19.96% year-over-year to -$243.8 million; the trailing twelve-month figure through Mar 2026 stood at -$243.8 million (up 19.96% YoY), and the FY2025 full-year result was -$276.1 million, up 7.45% from the prior year.
- Enterprise Value for Q1 2026 stood at -$243.8 million, up from -$276.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$243.8 million in Q1 2026 and bottomed at -$435.6 million in Q4 2022.
- The 5-year median for Enterprise Value is -$312.3 million (2023), against an average of -$330.9 million.
- The widest annual swing landed in 2022, when Enterprise Value tumbled 130.92%; it then advanced 28.3% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$435.6 million in 2022, then increased by 28.3% to -$312.3 million in 2023, then climbed by 4.5% to -$298.3 million in 2024, then increased by 7.45% to -$276.1 million in 2025, then grew by 11.7% to -$243.8 million in 2026.
- The last three Enterprise Value figures came in at -$243.8 million (Q1 2026), -$276.1 million (Q4 2025), and -$288.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -243.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -243.79 Mn |
| Dec 31, 2025 | -276.08 Mn |
| Sep 30, 2025 | -288.40 Mn |
| Jun 30, 2025 | -300.66 Mn |
| Mar 31, 2025 | -304.59 Mn |
| Dec 31, 2024 | -298.31 Mn |
| Sep 30, 2024 | -318.91 Mn |
| Jun 30, 2024 | -408.41 Mn |
| Mar 31, 2024 | -393.76 Mn |
| Dec 31, 2023 | -312.35 Mn |
| Sep 30, 2023 | -296.67 Mn |
| Jun 30, 2023 | -317.25 Mn |
| Mar 31, 2023 | -389.74 Mn |
| Dec 31, 2022 | -435.62 Mn |
| Sep 30, 2022 | -355.93 Mn |
| Jun 30, 2022 | -292.73 Mn |
| Mar 31, 2022 | -392.53 Mn |
| Dec 31, 2021 | -414.48 Mn |
| Sep 30, 2021 | -486.65 Mn |
| Jun 30, 2021 | -193.67 Mn |
| Mar 31, 2021 | -169.99 Mn |
| Dec 31, 2020 | -118.70 Mn |
| Sep 30, 2020 | -62.02 Mn |
| Jun 30, 2020 | -104.34 Mn |